The DOI matches its Crossref record; 76 of the 76 references it cites were found in a registry or an index.
Antibody targeted drugs as cancer therapeutics
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Continuous cultures of fused cells secreting antibody of predefined specificity
KÖHLER, G., & MILSTEIN, C. (1975) · Nature · doi:10.1038/256495a0 · Cited by 17,229
Engineered antibody fragments and the rise of single domains
Holliger, P., & Hudson, P. J. (2005) · Nature Biotechnology · doi:10.1038/nbt1142 · Cited by 1,931
Maxfield, F. R., & McGraw, T. E. (2004) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1315 · Cited by 1,729
Ligand-targeted therapeutics in anticancer therapy
Allen, T. M. (2002) · Nature Reviews Cancer · doi:10.1038/nrc903 · Cited by 1,647
Making antibodies by phage display technology
Winter, G., Griffiths, A. D., Hawkins, R. E., & Hoogenboom, H. R. (1994) · Annual Review of Immunology · doi:10.1146/annurev.iy.12.040194.002245 · Cited by 1,573
Reshaping human antibodies for therapy
Riechmann, L., Clark, M., Waldmann, H., & Winter, G. (1988) · Nature · doi:10.1038/332323a0 · Cited by 1,562
Effects of Drug Loading on the Antitumor Activity of a Monoclonal Antibody Drug Conjugate
Hamblett, K. J., Senter, P. D., Chace, D. F., Sun, M. M. C., Lenox, J., Cerveny, C. G., Kissler, K. M., Bernhardt, S. X., Kopcha, A. K., Zabinski, R. F., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0789 · Cited by 1,247
Monoclonal antibody therapy of cancer
Adams, G. P., & Weiner, L. M. (2005) · Nature Biotechnology · doi:10.1038/nbt1137 · Cited by 1,246
Development of potent monoclonal antibody auristatin conjugates for cancer therapy
Doronina, S. O., Toki, B. E., Torgov, M. Y., Mendelsohn, B. A., Cerveny, C. G., Chace, D. F., DeBlanc, R. L., Gearing, R. P., Bovee, T. D., Siegall, C. B., et al. (2003) · Nature Biotechnology · doi:10.1038/nbt832 · Cited by 1,206
Arming antibodies: prospects and challenges for immunoconjugates
Wu, A. M., & Senter, P. D. (2005) · Nature Biotechnology · doi:10.1038/nbt1141 · Cited by 1,052
Antibody mediated in vivo delivery of small interfering RNAs via cell-surface receptors
Song, E., Zhu, P., Lee, S.-K., Chowdhury, D., Kussman, S., Dykxhoorn, D. M., Feng, Y., Palliser, D., Weiner, D. B., Shankar, P., et al. (2005) · Nature Biotechnology · doi:10.1038/nbt1101 · Cited by 1,021
Schiffelers, R. M. (2004) · Nucleic Acids Research · doi:10.1093/nar/gnh140 · Cited by 901
Approval summary: gemtuzumab ozogamicin in relapsed acute myeloid leukemia.
Bross, P. F., Beitz, J. G., Chen, G., Chen, X., Duffy, E. J., Kieffer, L. V., Roy, S., Sridhara, R. N., Rahman, A., Williams, G., et al. (2001) · PubMed · Cited by 855
Improving the efficacy of antibody-based cancer therapies
Carter, P. (2001) · Nature Reviews Cancer · doi:10.1038/35101072 · Cited by 833
Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.
Yokota, T., Milenic, D. E., Whitlow, M. D., & Schlom, J. (1992) · PubMed · Cited by 819
Schneider, P., Holler, N., Bodmer, J.-L., Hahne, M., Frei, K., Fontana, A., & Tschopp, J. (1998) · The Journal of Experimental Medicine · doi:10.1084/jem.187.8.1205 · Cited by 812
Lienard, D., Ewalenko, P., Delmotte, J. J., Renard, N., & Lejeune, F. J. (1992) · Journal of Clinical Oncology · doi:10.1200/jco.1992.10.1.52 · Cited by 719
Drug therapy for acute myeloid leukemia
Tallman, M. S., Gilliland, D. G., & Rowe, J. M. (2005) · Blood · doi:10.1182/blood-2005-01-0178 · Cited by 661
Neri, D., & Bicknell, R. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1627 · Cited by 600
Sievers, E. L., Appelbaum, F. R., Spielberger, R. T., Forman, S. J., Flowers, D., Smith, F. O., Shannon-Dorcy, K., Berger, M. S., & Bernstein, I. D. (1999) · Blood · doi:10.1182/blood.v93.11.3678 · Cited by 512
Recent advances in tumor-targeting anticancer drug conjugates
Jaracz, S., Chen, J., Kuznetsova, L. V., & Ojima, I. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2005.04.084 · Cited by 490
Rosenberg, S. A., Yang, J. C., White, D. E., & Steinberg, S. M. (1998) · Annals of Surgery · doi:10.1097/00000658-199809000-00004 · Cited by 485
Oh, P., Li, Y., Yu, J., Durr, E., Krasinska, K. M., Carver, L. A., Testa, J. E., & Schnitzer, J. E. (2004) · Nature · doi:10.1038/nature02580 · Cited by 475
Antibody-targeted radiation cancer therapy
Milenic, D. E., Brady, E. D., & Brechbiel, M. W. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1413 · Cited by 380
Therapeutic monoclonal antibodies
Breedveld, F. (2000) · The Lancet · doi:10.1016/s0140-6736(00)01034-5 · Cited by 359
Clinical Trials: IL-12 Deaths: Explanation and a Puzzle
Cohen, J. (1995) · Science · doi:10.1126/science.270.5238.908a · Cited by 332 · cited 1×
“As a result, systemic administration of cytokine doses that mimic this physiological mode of action are frequently accompanied by severe side effect”
BackgroundMonoclonal antibodies as therapeutic agents for cancer
Harris, M. (2004) · The Lancet Oncology · doi:10.1016/s1470-2045(04)01467-6 · Cited by 320
(2000) · PubMed · Cited by 295
In vivo Drug-Linker Stability of an Anti-CD30 Dipeptide-Linked Auristatin Immunoconjugate
Sanderson, R. J., Hering, M. A., James, S. F., Sun, M. M. C., Doronina, S. O., Siadak, A. W., Senter, P. D., & Wahl, A. F. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.843.11.2 · Cited by 285
Antibody directed enzymes revive anti-cancer prodrugs concept
Bagshawe, K. (1987) · British Journal of Cancer · doi:10.1038/bjc.1987.237 · Cited by 280
Targeted drug conjugates: principles and progress
Garnett, M. C. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00227-7 · Cited by 262
BiTEs: bispecific antibody constructs with unique anti-tumor activity
Wolf, E., Hofmeister, R., Kufer, P., Schlereth, B., & Baeuerle, P. A. (2005) · Drug Discovery Today · doi:10.1016/s1359-6446(05)03554-3 · Cited by 260
Selective targeted delivery of TNFα to tumor blood vessels
Borsi, L., Balza, E., Carnemolla, B., Sassi, F., Castellani, P., Berndt, A., Kosmehl, H., Birò, A., Siri, A., Orecchia, P., et al. (2003) · Blood · doi:10.1182/blood-2003-04-1039 · Cited by 234
Increased affinity leads to improved selective tumor delivery of single-chain Fv antibodies.
Adams, G. P., Schier, R., Marshall, K., Wolf, E. J., McCall, A. M., Marks, J. D., & Weiner, L. M. (1998) · PubMed · Cited by 230
Schwartz, R. S. (2004) · New England Journal of Medicine · doi:10.1056/nejmp048021 · Cited by 221
Eradication of large colon tumor xenografts by targeted delivery of maytansinoids.
Liu, C., Tadayoni, B. M., Bourret, L. A., Mattocks, K. M., Derr, S. M., Widdison, W. C., Kedersha, N. L., Ariniello, P. D., Goldmacher, V. S., Lambert, J. M., et al. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.16.8618 · Cited by 196
Schrama, D., thor Straten, P., Fischer, W. H., McLellan, A. D., Bröcker, E.-B., Reisfeld, R. A., & Becker, J. C. (2001) · Immunity · doi:10.1016/s1074-7613(01)00094-2 · Cited by 192
Self-citationSelective activation of anticancer prodrugs by monoclonal antibody–enzyme conjugates
Senter, P. D., & Springer, C. J. (2001) · Advanced Drug Delivery Reviews · doi:10.1016/s0169-409x(01)00206-x · Cited by 178
Halin, C., Gafner, V., Villani, M. E., Borsi, L., Berndt, A., Kosmehl, H., Zardi, L., & Neri, D. (2003) · PubMed · Cited by 168
Francis, R. J., Sharma, S. K., Springer, C., Green, A. J., Hope-Stone, L. D., Sena, L., Martin, J., Adamson, K. L., Robbins, A., Gumbrell, L., et al. (2002) · British Journal of Cancer · doi:10.1038/sj.bjc.6600517 · Cited by 163
Tumor-activated Prodrugs—A New Approach to Cancer Therapy
Denny, W. A. (2004) · Cancer Investigation · doi:10.1081/cnv-200027148 · Cited by 162
Thorpe, P. E., Wallace, P. M., Knowles, P. P., Relf, M., Brown, A. N., Watson, G., Blakey, D. C., & Newell, D. R. (1988) · PubMed · Cited by 155
Monoclonal Antibodies: A Powerful New Tool in Biology and Medicine
Yelton, D. E., & Scharff, M. D. (1981) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.50.070181.003301 · Cited by 136
Fas receptor‐mediated apoptosis: a clinical application?
Timmer, T., de Vries, E. G. E., & de Jong, S. (2001) · The Journal of Pathology · doi:10.1002/path.1028 · Cited by 129
Papac, R. J. (2001) · PubMed Central · Cited by 123
Engineered vascular‐targeting antibody‐interferon‐γ fusion protein for cancer therapy
Ebbinghaus, C., Ronca, R., Kaspar, M., Grabulovski, D., Berndt, A., Kosmehl, H., Zardi, L., & Neri, D. (2005) · International Journal of Cancer · doi:10.1002/ijc.20952 · Cited by 117
Bremer, E., Samplonius, D. F., van Genne, L., Dijkstra, M. H., Kroesen, B. J., de Leij, L. F. M. H., & Helfrich, W. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m413673200 · Cited by 98
Neal, Z. C., Yang, J. C., Rakhmilevich, A. L., Buhtoiarov, I. N., Lum, H. E., Imboden, M., Hank, J. A., Lode, H. N., Reisfeld, R. A., Gillies, S. D., et al. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0799 · Cited by 95
Self-citationKipriyanov, S. M., Cochlovius, B., Schäfer, H., Moldenhauer, G., Bähre, A., Gall, F. L., Knackmuss, S. H. J., & Little, M. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.1.137 · Cited by 91
Becker, J. C., Pancook, J. D., Gillies, S. D., Mendelsohn, J. M., & Reisfeld, R. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.7.2702 · Cited by 91
Self-citationBremer, E., Samplonius, D. F., Peipp, M., van Genne, L., Kroesen, B., Fey, G. H., Gramatzki, M., de Leij, L. F. M. H., & Helfrich, W. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2756 · Cited by 90
Bispecific CD3 × CD19 diabody for T cell-mediated lysis of malignant human B cells
Kipriyanov, S. M., Moldenhauer, G., Strauß, G., & Little, M. (1998) · International Journal of Cancer · doi:10.1002/(sici)1097-0215(19980831)77:5<763::aid-ijc16>3.0.co;2-2 · Cited by 90
Cruz, J. S. D., Trinh, K. R., Morrison, S. L., & Penichet, M. L. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.165.9.5112 · Cited by 84
Dillman, R. O., Johnson, D. E., Shawler, D. L., & Koziol, J. (1988) · PubMed · Cited by 77
Nabhan, C., Rundhaugen, L. M., Riley, M. B., RADEMAKER, A. W., Boehlke, L., Jatoi, M., & Tallman, M. S. (2004) · Leukemia Research · doi:10.1016/j.leukres.2004.04.011 · Cited by 75
Samel, D., Müller, D., Gerspach, J., Assohou-Luty, C., Sass, G., Tiegs, G., Pfizenmaier, K., & Wajant, H. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m304866200 · Cited by 74
A Fully Human Antitumor ImmunoRNase Selective for ErbB-2-Positive Carcinomas
Lorenzo, C. D., Arciello, A., Cozzolino, R., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-3717 · Cited by 67
Bruenke, J., Barbin, K., Kunert, S., Lang, P., Pfeiffer, M. M., Stieglmaier, K., NIETHAMMER, D., Stockmeyer, B., Peipp, M., Repp, R., et al. (2005) · British Journal of Haematology · doi:10.1111/j.1365-2141.2005.05414.x · Cited by 63
Grosse‐Hovest, L., Hartlapp, I., Marwan, W., Brem, G., Rammensee, H., & Jung, G. (2003) · European Journal of Immunology · doi:10.1002/eji.200323322 · Cited by 62
Cytokine Gene Therapy or Infusion as Treatment for Solid Human Cancer
Robinson, B. W. S., Mukherjee, S., Davidson, A., Morey, S., Musk, A. W., Ramshaw, I. A., Smith, D. W., Lake, R., Haenel, T., Garlepp, M. J., et al. (1998) · Journal of Immunotherapy · doi:10.1097/00002371-199805000-00007 · Cited by 62
Herceptin-Geldanamycin Immunoconjugates
Mandler, R., Kobayashi, H., Hinson, E. R., Brechbiel, M. W., & Waldmann, T. A. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2485 · Cited by 60
Guillemard, V., & Saragovi, H. U. (2004) · Oncogene · doi:10.1038/sj.onc.1207463 · Cited by 57
Petersen, B. H., Deherdt, S. V., Schneck, D. W., et al. (1991) · PubMed · Cited by 54
Shen, W., Ballou, B. T., Ryser, H. J. ‐., & Hakala, T. R. (1986) · PubMed · Cited by 48
Tumor stroma-associated antigens for anti-cancer immunotherapy
Hofmeister, V., Vetter, C. S., Schrama, D., Bröcker, E., & Becker, J. C. (2005) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-005-0070-1 · Cited by 47
Self-citationInfluence of relative binding affinity on efficacy in a panel of anti-CD3 scFv immunotoxins
Hexham, J. M., Dudas, D., Hugo, R., Thompson, J., King, V., Dowling, C., Neville, D. M., Digan, M. E., & Lake, P. (2001) · Molecular Immunology · doi:10.1016/s0161-5890(01)00070-0 · Cited by 38
Advances in antibody-directed enzyme prodrug therapy.
Sharma, S. K., Bagshawe, K. D., & Beǵent, R. H. J. (2005) · PubMed · Cited by 32
Johnson, D. A., & Laguzza, B. C. (1987) · PubMed · Cited by 30
Gao, Y., Xiong, D., Yang, M., et al. (2004) · Leukemia · doi:10.1038/sj.leu.2403267 · Cited by 30
Wang, X.-B. (2004) · The Journal of Biochemistry · doi:10.1093/jb/mvh065 · Cited by 29
Moro, M., Gasparri, A. M., Pagano, S., Bellone, M., Tornaghi, P., Veglia, F., Corti, A., Casorati, G., & Dellabona, P. (1999) · PubMed · Cited by 28
Brignole, C., Marimpietri, D., Pagnan, G., Paolo, D. D., Zancolli, M., Pistoia, V., Ponzoni, M., & Pastorino, F. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.11.065 · Cited by 25
Cruz, J. S. D., Morrison, S. L., & Penichet, M. L. (2005) · Vaccine · doi:10.1016/j.vaccine.2005.04.041 · Cited by 23
Hombach, A. A., Heuser, C., & Abken, H. (2005) · International Journal of Cancer · doi:10.1002/ijc.20829 · Cited by 19
Shift from Systemic to Site-Specific Memory by Tumor-Targeted IL-2
Schrama, D., Xiang, R., Eggert, A. O., Andersen, M. H., Pedersen, L. Ø., Kämpgen, E., Schumacher, T. N., Reisfeld, R. R., & Becker, J. C. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.172.10.5843 · Cited by 15
Self-citationTechnology evaluation: cantuzumab mertansine
Smith, S. (2004) · Current opinion in molecular therapeutics · Cited by 8
Cited by
Factors affecting the clearance and biodistribution of polymeric nanoparticles
Alexis, F., Pridgen, E., Molnar, L. K., & Farokhzad, O. C. (2008) · Molecular Pharmaceutics · doi:10.1021/mp800051m · Cited by 3,699
Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy
Pérez-Herrero, E., & Fernández-Medarde, A. (2015) · European Journal of Pharmaceutics and Biopharmaceutics · doi:10.1016/j.ejpb.2015.03.018 · Cited by 1,875
Paul Ehrlich's magic bullet concept: 100 years of progress
Strebhardt, K., & Ullrich, A. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2394 · Cited by 1,457
Biodegradable synthetic polymers: Preparation, functionalization and biomedical application
Tian, H., Tang, Z., Zhuang, X., Chen, X., & Jing, X. (2012) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2011.06.004 · Cited by 1,293
Nichols, J. W., & Bae, Y. H. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.03.057 · Cited by 834
Metadata
- Authors
- Schrama, D., Reisfeld, R. A., & Becker, J. C.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2006-01-20
- Volume
- 5
- Issue
- 2
- Pages
- 147-159
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2083483697
- Cited by
- 768
- References
- 76
- FWCI
- 5.24
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.